{
  "symbol": "GEHC",
  "company": "GE HealthCare Technologies Inc.",
  "generated_at": "2026-06-24T07:36:48.054Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-05-12T00:48:15.672Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, concentration). The compressed valuation reflects real execution and margin risks rather than a market mispricing, making even an income structure too risky without clearer stabilization signals.",
      "trigger": "[insider_cluster_universe] 7 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-12T00:48:15.633Z",
      "skip": true,
      "reason": "Scored 14/100 due to weak insider conviction, deteriorating quality metrics (margin compression, 4.1x net debt/EBITDA), and active anti-signal gates (dilution, concentration). The compressed valuation reflects real execution and margin risks rather than a market mispricing, making even an income structure too risky without clearer stabilization signals.",
      "score": 14,
      "breakdown": {
        "smart_money": 3,
        "options_flow": 6,
        "catalyst": 0,
        "mispricing": 5,
        "quality": 0,
        "technical": 0
      },
      "debug_path": "drafts/2026-05-12-GEHC.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-12T00:47:28.523Z",
      "summary": "The investigation trigger was 7 Form 4 filings in 14 days, but on close inspection ALL were director RSU grants (code A) — not open-market purchases. One genuine CFO open-market purchase exists ($200K+ at $60.60 on May 1). The stock crashed ~13% on April 29 after a Q1 EPS miss and guidance cut driven by supply-chain cost inflation and a supplier quality recall in Pharma Diagnostics. Technicals are deeply oversold (RSI 35.5), forward P/E is compressed to 11.5x, analysts still target $80, and the stock sits ~31% below its 52-week high — creating an attractive covered-call income setup at elevated IV rather than a directional long.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 23,
      "walltime_min": 16,
      "debug_path": "dossiers/2026-05-12-GEHC.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "GEHC",
    "call": "SELL",
    "confidence": 5,
    "score": -6,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_down": "-1 (-10.6%)",
      "rsi_neutral": "0 (50.3)",
      "recent_macd_bearish_cross": "-2 (2d ago)",
      "from_high": "0 (-27.7%)"
    },
    "summary": "SELL (score -6) · 12-1 mom -10.6% · RSI 50.3 · below_both · -27.7% from high",
    "last_close": 63.72,
    "one_month_ago_close": 64.33,
    "twelve_month_ago_close": 71.98,
    "twelve_one_momentum_pct": -10.63,
    "rsi_14": 50.3,
    "ma_stack": "below_both",
    "from_period_high_pct": -27.72,
    "period_high": 88.16,
    "price_targets": {
      "bear": 61.71,
      "fair": 69.47,
      "bull": 101.38,
      "bear_return_pct": -3.2,
      "fair_return_pct": 9,
      "bull_return_pct": 59.1,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 65,
        "target_mean": 79.73684,
        "target_high": 98,
        "analyst_count": 19
      }
    },
    "generated_at": "2026-06-24T07:36:48.050Z"
  }
}